NCT03773393View on ClinicalTrials.gov

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

May 25, 2027

Study Completion Date

May 30, 2027

Conditions
Bone Marrow Disease
Interventions
BIOLOGICAL

CK0801

CK0801 (a Cord blood-derived T-regulatory cell product)

Trial Locations (2)

77030

The University of Texas MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Research Center, Cancer Center of Southern California, Santa Monica

Sponsors

Lead Sponsor

Cellenkos, Inc.
All Listed Sponsors
lead

Cellenkos, Inc.

INDUSTRY